ADMA Biologics, Inc. (ADMA) Stock Analysis — Probabli.AI
AI-powered analysis for ADMA (ADMA Biologics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $14.32 · Market cap: $3.6B · AI outlook: Bullish
ADMA Biologics demonstrates compelling fundamentals underpinned by its extraordinary revenue growth rate, consistent earnings beats, and favorable industry dynamics. With its innovative product pipeline and strategic partnerships, the stock is positioned to outperform the market over medium to long-term horizons. Despite some operational and competitive risks, the bullish trajectory is strongly…
Probabilistic 1-Year Outlook
- Bull 50% · Neutral 35% · Bear 15%
- 1-year price estimates — P10: $11 / P50: $24 / P90: $35
- ADMA Biologics is projected to perform strongly in the next year due to its remarkable revenue growth estimates, consistent earnings beat streak, significant analyst price target, and positive news catalysts such as…
5-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 5-year price estimates — P10: $10 / P50: $60 / P90: $125
SWOT Highlights
- Strength: Exceptional revenue growth rate.
- Strength: Regulatory approval of new products.
- Risk: High susceptibility to supply chain disruptions.
- Risk: Reliance on raw materials with rising costs.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
1 Wall Street analyst rate ADMA a STRONG BUY with a mean price target of $32.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ADMA forecast details · ADMA sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- ADMA Biologics, Inc. (ADMA) — saved
ADMA Biologics demonstrates compelling fundamentals underpinned by its extraordinary revenue growth rate, consistent earnings beats, and favorable industry dynamics. With its innovative product pipeline and strategic partnerships, the stock
- ADMA Biologics, Inc. (ADMA) — saved
ADMA Biologics, Inc. presents high growth potential supported by significant revenue expansion, consistent execution excellence, and strategic positioning. Key risks include cash flow management and supply chain concerns, but the company's
- ADMA Biologics, Inc. (ADMA) — saved
ADMA Biologics showcases robust short- and long-term growth potential, buoyed by regulatory successes, strong product pipelines, and analyst confidence, alongside some sector-related vulnerabilities.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.